|
⚲
|
| Keyboard |
| RA Capital Management LLC
✚
|
|
|---|---|
| CRD # | 138410 |
| SEC # | 801-66659 |
| CIK # | 0001346824 |
| AUM | |
| Employees | |
| Fees | |
| Minimum | |
| Phone | 617-778-2512 |
| Address | 111 Huntington Avenue Boston, MA 02199 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($M) |
|---|
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Ascendis Pharma A/S | 2.4 | ||
| Vaxcyte Inc | 0.7 | ||
| Rhythm Pharmaceuticals Inc | 0.6 | ||
| TYRA Biosciences Inc | 0.5 | ||
| Sionna Therapeutics Inc | 0.4 | ||
| Edgewise Therapeutics Inc | 0.3 | ||
| Newamsterdam Pharma Co NV | 0.3 | ||
| Nuvalent Inc | 0.3 | ||
| Magenta Therapeutics Inc | 0.2 | ||
| Mineralys Therapeutics Inc | 0.2 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 0 | 0.0 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 2 | 53.9 |
| By Discretionary | ||
| Discretionary | 2 | 53.9 |
| Non-Discretionary | 0 | 0.0 |
| Total | 2 | 53.9 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 53.9 | |
| Total | 2 | 53.9 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001346824] | |
| 3 | [0001346824] | |
| 4 | [0001346824] | |
| SC 13D | [0001346824] | |
| SC 13G | [0001346824] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.1B |
| Serves | Institutional |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Wave Life Sciences Ltd WVE
Ordinary Shares
|
2026-03-30 | Buy | 971,091 | $6.50 | 6,312,092 |
|
Mineralys Therapeutics Inc MLYS
Common Stock
|
2026-03-30 | Buy | 58,300 | $24.16 | 1,408,528 |
|
Mineralys Therapeutics Inc MLYS
Common Stock
|
2026-03-27 | Buy | 310,700 | $23.67 | 7,354,269 |
|
Wave Life Sciences Ltd WVE
Ordinary Shares
|
2026-03-27 | Buy | 2,495,623 | $6.43 | 16,046,856 |
|
Wave Life Sciences Ltd WVE
Ordinary Shares
|
2026-03-26 | Buy | 4,954,558 | $6.06 | 30,024,621 |
|
Wave Life Sciences Ltd WVE
Ordinary Shares
|
2026-03-26 | Buy | 351,224 | $6.38 | 2,240,809 |
|
Acumen Pharmaceuticals Inc ABOS
Common Stock
|
2026-03-16 | Grant | 6,060,606 | $3.30 | 20,000,000 |
|
Bicara Therapeutics Inc BCAX
Common Stock
|
2026-02-26 | Buy | 300,000 | $16.00 | 4,800,000 |
|
Bicara Therapeutics Inc BCAX
Pre-Funded Warrant (Right to Buy) · derivative
|
2026-02-26 | Buy | 2,200,000 | $16.00 | 35,200,000 |
|
Mineralys Therapeutics Inc MLYS
Common Stock
|
2026-02-19 | Grant | 6,200 | $0.00 | |
|
Mineralys Therapeutics Inc MLYS
Stock Option (Right to Buy) · derivative
|
2026-02-19 | Grant | 8,300 | $0.00 | |
|
Evommune Inc EVMN
Common Stock
|
2026-02-17 | Grant | 35,868 | $27.88 | 1,000,000 |
|
SpyGlass Pharma Inc SGP
Series C-2 Preferred Stock · derivative
|
2026-02-09 | Conversion | 767,294 | ||
|
SpyGlass Pharma Inc SGP
Common Stock
|
2026-02-09 | Buy | 3,441,966 | $16.00 | 55,071,456 |
|
SpyGlass Pharma Inc SGP
Series C-2 Preferred Stock · derivative
|
2026-02-09 | Conversion | 1,150,941 | ||
|
SpyGlass Pharma Inc SGP
Common Stock
|
2026-02-09 | Buy | 248,034 | $16.00 | 3,968,544 |
|
SpyGlass Pharma Inc SGP
Common Stock
|
2026-02-09 | Conversion | 1,806,644 | ||
|
SpyGlass Pharma Inc SGP
Series D Preferred Stock · derivative
|
2026-02-09 | Conversion | 222,591 | ||
|
SpyGlass Pharma Inc SGP
Series D Preferred Stock · derivative
|
2026-02-09 | Conversion | 272,056 | ||
|
SpyGlass Pharma Inc SGP
Common Stock
|
2026-02-09 | Conversion | 2,524,473 | ||
| showing 20 of 200 most recent transactions | |||||